AstraZeneca and Oncoshot have signed a commercial partnership agreement which allows AstraZeneca to harness Oncoshot’s InSite Feasibilitydigital platform to swiftly initiate trials that are most relevant to cancer patients in Singapore.
The platform facilitates the efficient completion of oncology feasibility studies supported by near real-time insights. Feasibility studies are typically conducted by clinical trial sponsors such as pharmaceutical companies before trial initiation to assess the suitability of specific trial sites.
Powered by Oncoshot’s Artificial Intelligence-enabled patient-to-trial matching technology, InSite Feasibility translates the de-identified data of Singapore’s cancer population into precise analytics that can help catalyse cancer research.
The data, which is regularly updated, covers a significant number of newly diagnosed cancer patients in Singapore over two years.
AstraZeneca has been active in developing healthcare innovation partnerships and has launched health innovation hubs around the world, known as the A.Catalyst Network.
Under this initiative, AstraZeneca has signed MoUs earlier in February 2020 with leading healthcare innovators and organisations, focusing on using AI, big data and genomics to help people with diabetes, heart disease and cancer.
The collaboration with Oncoshot is yet another opportunity to support and contribute to Singapore’s innovation initiatives, such as the National AI Strategy, where they continue to leverage AI to drive better health outcomes and create new economic opportunities in Singapore.
While conducting feasibility studies can help improve chances of successful enrolment, the existing paradigm for feasibility studies largely involves the use of historical data, which may be outdated and inaccurate.
In an effort to mitigate this challenge and gain sharper insights into Singapore’s cancer population, Oncoshot works closely with public and private hospitals, where clinical trials are typically conducted, to match anonymised patient profiles to its database of cancer trials. Obtained in real time, the resulting analytics reveal whether a trial site has suitable patient populations for trials, according to highly specific criteria.
Aside from presenting such population-level insights, InSite Feasibility also facilitates seamless collaboration between trial sites and sponsors to complete feasibility studies within a 72-hour time frame. The company aims to streamline the process of assessing cancer trial feasibility within the local healthcare context.
“Today, novel cancer therapies are being developed at an unprecedented rate, and the only way to stay at the forefront of this fast-evolving field is by leveraging accurate data analytics to grow the clinical trial ecosystem,” said Huren Sivaraj, CEO and co-founder of Oncoshot.
